Navigation Links
MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration
Date:7/9/2009

MOUNTAIN VIEW, Calif., July 9 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has received a notice of termination of the license agreement with AstraZeneca related to the company's Unit Dose Budesonide (UDB) product candidate. The termination was received on July 8, 2009, effective immediately. All rights licensed to AstraZeneca in the agreement now revert to the company. MAP Pharmaceuticals plans to suspend development of UDB, which did not meet primary endpoints in a Phase 3 trial in children 12-months to eight years of age with mild asthma.

"Physicians and parents continue to express a need for improved therapies for pediatric asthma that offer faster nebulization times, lower doses of steroid exposure, improved treatment compliance and reduced side effects when compared to currently available therapies. MAP Pharmaceuticals is considering options for its pediatric asthma program moving forward, including the development of a next generation therapy with budesonide," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "Separately, MAP Pharmaceuticals remains focused on developing our LEVADEX(TM) migraine therapy, which recently achieved all four primary endpoints in a Phase 3 clinical trial, with the goal of bringing this differentiated treatment to the many patients who suffer from the debilitating effects of migraine."

MAP Pharmaceuticals will provide updated financial guidance for 2009 in its second quarter results release. MAP Pharmaceuticals finished the first quarter of 2009 with cash and cash equivalents of $67.7 million and $4.7 million in accounts receivables.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums
2. Portola Pharmaceuticals to Host Conference Call at 11:00 a.m. Eastern Time Tomorrow to Discuss Betrixaban Partnership and Provide Corporate Update
3. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
4. Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment
5. Arena Pharmaceuticals Announces Public Offering of Common Stock
6. Solvay Pharmaceuticals, Inc. Announces Commercial Availability of CREON(R) (Pancrelipase) Delayed-Release Capsules
7. Jazz Pharmaceuticals Pays Accrued Interest Under Senior Secured Notes
8. Jazz Pharmaceuticals Completes $7 Million Private Placement
9. Biostar Pharmaceuticals, Inc. Commences the Full Implementation of New Rural Cooperative Supply Network Plan
10. ADVENTRX Pharmaceuticals Announces Closing of Financing
11. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Study of MM-111, a Bispecific Antibody to ErbB2/3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... York, NY (PRWEB) August 20, 2014 ... filed on behalf of women who were allegedly injured ... move forward in New Jersey’s Bergen County Superior Court, ... Order issued on August 15, 2014, the Court has ... files for Mirena lawsuits that are part of the ...
(Date:8/20/2014)... Aug. 20, 2014 (HealthDay News) -- Loss of brain ... explain why many seniors have trouble falling and staying ... sleep disruption can be especially severe and often results ... The investigators analyzed data from the Rush Memory ... enrolled at age 65 and are being followed until ...
(Date:8/20/2014)... Kathleen Doheny HealthDay Reporter ... reconstruction after a mastectomy has long been an option, but ... women choose it. "The most common reasons women didn,t ... weren,t interested in more surgery or they were focused on ... of breast surgery at Memorial Sloan Kettering Cancer Center, in ...
(Date:8/20/2014)... deadliest infectious diseases in the world, killing one to ... tuberculosis have long debated its origins. New research shows ... seals and sea lions that brought the disease to ... before Europeans landed on the continent. , The paper, ... New World Human Tuberculosis," was published in Nature ...
(Date:8/20/2014)... August 20, 2014 With 3943.8% growth, Connexion ... of the nation’s fastest growing companies. The Inc. 500 ranks ... care sector. Connexion Point is the #1 fastest growing company ... Medicare and Medicaid, and its clients include four of the ... employs 1,000 people and has offices and contact centers in ...
Breaking Medicine News(10 mins):Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 4Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2
... Acquisition Will Provide Market-Leading Dental Tools and Services to ... ... 29 WellPoint, Inc. (NYSE:,WLP), the nation,s largest health benefits ... country,s largest administrators,of dental benefit plans. DeCare, a Minneapolis-based company, ...
... 29 Birner Dental Management,Services, Inc. (Nasdaq: ... conduct a conference call to review first quarter ... teleconference may include,discussion of management,s expectations of future ... on Tuesday, May 13, 2008 at 9:00 a.m. ...
... Parallel caret ,R, Software Provides Faster Analysis of Safety ... ... IT World Conference and Exposition,-- REvolution Computing, the leading provider ... results of "A,Benchmark Study of Large-Scale Chemical Classification on Quad-Core ...
... more realistically according to a new study accepted for ... (JCEM). The study revealed that anti-Mllerian hormone (AMH) levels ... able to specify a womans reproductive age more accurately ... in the blood reflect the number of small follicles ...
... A New LTCI Presentation System Designed for Today,s ... LLC, the leader in,providing long-term care insurance sales, ... announced the release of,simplifyingLTC, a LTCI presentation system ... presentation system communicates the risk of long-term care ...
... to manage nation,s ... IT solution will administer payments to health care providers, enable, electronic health ... ... EDS, the recognized leader,in providing health care support to state governments, has ...
Cached Medicine News:Health News:WellPoint Announces Acquisition of DeCare Dental 2Health News:WellPoint Announces Acquisition of DeCare Dental 3Health News:WellPoint Announces Acquisition of DeCare Dental 4Health News:WellPoint Announces Acquisition of DeCare Dental 5Health News:Pfizer Partners with REvolution Computing to Improve Medicine Production Pipeline 2Health News:Pfizer Partners with REvolution Computing to Improve Medicine Production Pipeline 3Health News:SellingLTC.com Develops simplifyingLTC 2Health News:EDS Returns to Georgia With $391 Million Medicaid Win 2Health News:EDS Returns to Georgia With $391 Million Medicaid Win 3
(Date:8/20/2014)... -- The National Necrotizing Fasciitis Foundation (NNFF) today announced that ... treated for a life threatening form of necrotizing fasciitis, or ... Medical Director of Inpatient Wound Care and founder of The ... Rancho Mirage, California . Dr. Gauto ... at Seton Hospital in Daly City, California ...
(Date:8/20/2014)... , Aug. 20, 2014 ... of the "Global Advanced Wound Care and ... - Size, Share, Global Trends, Company Profiles, Demand, ... 2013 - 2020" report to their offering. ... advanced wound care and closure market (types, applications, ...
(Date:8/20/2014)... and PHOENIX , Aug. ... to bring cutting-edge next-generation sequencing and proteomic diagnostics ... today announced a collaboration with TESARO, Inc.  Paradigm ... patient tissue samples from clinical trials to better ... to TESARO,s TSR-011.  This may lead to more successful ...
Breaking Medicine Technology:Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 2Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 3Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 4Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 5Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 6Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2
... Reliability, quality and convenience make ... workhorse for the small workload laboratory. ... with a capacity of 26 tests ... a throughput up 200 tests per ...
The Advia IMS integrates a full menu of both immunoassay and chemistry tests....
... Diagnostics Task Targeted Automation VS II ... pre- and post-analytical steps in the ... primary tubes and aliquoting into bar ... and extendable to future needs. Works ...
... Task Targeted Automation PSD 1 ... of pre- and post-analytical steps ... / archiving of primary tubes ... labeled secondary tubes. Fully scalable ...
Medicine Products: